SOX2 has also been implicated in endocrine resistance in breast cancer (12) and in the development of chemo-resistance in gastric cancer (40), glioblastoma (41), head and neck squamous cell carcinoma (42), lung cancer (43), and prostate cancer (44). This evidence concerns the gene SOX2 and prostate cancer.